Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Viking Therapeutics (VKTX) and Axsome Therapeutics (AXSM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agenus (AGEN – Research Report), Viking Therapeutics (VKTX – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments. Agenus (AGEN) In a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Agenus. The company's shares closed last Friday at $5.26. According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics. Currently, the analyst consensus on Agenus is a Moderate Buy with an average price target of $8.00, representing a 53.0% upside. In a report issued on June 7, B.Riley Financial also reiterated a Buy rating on the stock with a $8.00 price target. See today’s analyst top recommended stocks >> Viking Therapeutics (VKTX) William Blair analyst Andy Hsieh reiterated a Buy rating on Viking Therapeutics yesterday. The company's shares closed last Friday at $6.14. According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 11.5% and a 53.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Vaccitech Plc Sponsored ADR, Actinium Pharmaceuticals, and Nektar Therapeutics. Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.10, which is a 136.5% upside from current levels. In a report released today, B.Riley Financial also maintained a Buy rating on the stock with a $15.00 price target. Axsome Therapeutics (AXSM) In a report issued on June 15, Myles Minter from William Blair reiterated a Buy rating on Axsome Therapeutics. The company's shares closed last Friday at $67.35. According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences. Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $135.33, representing a 104.1% upside. In a report issued on June 10, Berenberg Bank also initiated coverage with a Buy rating on the stock with a $112.00 price target. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. The post Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Viking Therapeutics (VKTX) and Axsome Therapeutics (AXSM) appeared first on TipRanks Financial Blog.

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agenus (AGEN – Research Report), Viking Therapeutics (VKTX – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments.

Agenus (AGEN)

In a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Agenus. The company's shares closed last Friday at $5.26.

According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics.

Currently, the analyst consensus on Agenus is a Moderate Buy with an average price target of $8.00, representing a 53.0% upside. In a report issued on June 7, B.Riley Financial also reiterated a Buy rating on the stock with a $8.00 price target.

Viking Therapeutics (VKTX)

William Blair analyst Andy Hsieh reiterated a Buy rating on Viking Therapeutics yesterday. The company's shares closed last Friday at $6.14.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 11.5% and a 53.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Vaccitech Plc Sponsored ADR, Actinium Pharmaceuticals, and Nektar Therapeutics.

Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.10, which is a 136.5% upside from current levels. In a report released today, B.Riley Financial also maintained a Buy rating on the stock with a $15.00 price target.

Axsome Therapeutics (AXSM)

In a report issued on June 15, Myles Minter from William Blair reiterated a Buy rating on Axsome Therapeutics. The company's shares closed last Friday at $67.35.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $135.33, representing a 104.1% upside. In a report issued on June 10, Berenberg Bank also initiated coverage with a Buy rating on the stock with a $112.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The post Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Viking Therapeutics (VKTX) and Axsome Therapeutics (AXSM) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

William Blair Sticks to Their Buy Rating for Biogen (BIIB)

William Blair analyst Matt Phipps reiterated a Buy rating on Biogen (BIIB – Research Report) on June 15. The company's shares closed last Friday at $388.44. According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics. Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $428.09, which is a 10.6% upside from current levels. In a report issued on June 3, Jefferies also assigned a Buy rating to the stock with a $450.00 price target. See today’s analyst top recommended stocks >> The company has a one-year high of $468.55 and a one-year low of $223.25. Currently, Biogen has an average volume of 1.7M. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The post William Blair Sticks to Their Buy Rating for Biogen (BIIB) appeared first on TipRanks Financial Blog.

William Blair analyst Matt Phipps reiterated a Buy rating on Biogen (BIIB – Research Report) on June 15. The company's shares closed last Friday at $388.44.

According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics.

Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $428.09, which is a 10.6% upside from current levels. In a report issued on June 3, Jefferies also assigned a Buy rating to the stock with a $450.00 price target.

The company has a one-year high of $468.55 and a one-year low of $223.25. Currently, Biogen has an average volume of 1.7M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

The post William Blair Sticks to Their Buy Rating for Biogen (BIIB) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.